GSK, Shionogi To Develop Longer-Acting HIV Treatment

Reuters (9/28, Aripaka) reports GlaxoSmithKline “said on Tuesday it would develop an HIV treatment with Japan’s Shionogi for use in regimens with dosing gaps of three months or more.” GSK “said...it would pay Shionogi 20 million pounds ($27.36 million) up...